|
|
|
|
|
|
by warrenmar
3827 days ago
|
|
|
There's a paper in the Clinical Chemistry and Laboratory Medicine journal titled, "Theranos phenomenon: promises and fallacies" [1]. It says most of the cost are related to overhead and personnel, not technology. Consumables are cheap. Also it is entirely possible that tests are being subsidized with VC money currently. I don't know what they would have to charge to be cash flow positive. [1] http://www.degruyter.com/view/j/cclm.2015.53.issue-7/cclm-20... |
|
|